Curat Global LLC Buys New Holdings in Novo Nordisk A/S (NYSE:NVO)

Curat Global LLC bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,830 shares of the company's stock, valued at approximately $266,000.

Several other hedge funds and other institutional investors have also modified their holdings of NVO. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $29,000. Transce3nd LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 2.8%

NYSE NVO traded up $2.05 on Friday, reaching $74.70. The company had a trading volume of 9,535,540 shares, compared to its average volume of 6,891,503. The company's fifty day moving average is $65.87 and its 200-day moving average is $80.71. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market capitalization of $335.22 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.